Kras g12c inhibitors and methods of using the same
US-2019374542-A1 · Dec 12, 2019 · US
KRAS G12C inhibitors and methods of using the same
US11090304B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11090304-B2 |
| Application number | US-201916402538-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 3, 2019 |
| Priority date | May 4, 2018 |
| Publication date | Aug 17, 2021 |
| Grant date | Aug 17, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
First claim
Opening claim text (preview).
What is claimed: 1. A compound having a structure selected from:
Assignees
Inventors
- Allen John Gordon
- Allen Jennifer Rebecca
- Minatti Ana Elena
- Xue Qiufen
- Wurz Ryan Paul
- Tegley Christopher M
- Pickrell Alexander J
- Nguyen Thomas T
- Ma Vu Van
- Lopez Patricia
- Liu Longbin
- Kopecky David John
- Frohn Michael J
- Chen Ning
- Chen Jian Jeffrey
- Siegmund Aaron C
- Amegadzie Albert
- Tamayo Nuria A
- Booker Shon
- Goodman Clifford
- Walton Mary
- Nishimura Nobuko
- Shin Youngsook
- Low Jonathan D
- Cee Victor J
- Reed Anthony B
- Wang Hui-Ling
- Lanman Brian Alan
Classifications
directly linked by a ring-member-to-ring-member bond · CPC title
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title
Ortho-condensed systems · CPC title
- A61K31/517Primary
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11090304B2 cover?
- Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/517. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).